Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Urinary Bladder Neoplasms 5Melanoma 2Glioblastoma 2Brain Neoplasms 2Urothelial Carcinoma of the Bladder 1Squamous Cell Carcinoma of Head and Neck 1Oligodendroglioma 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Neuroblastoma 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lymphoma, Follicular 1Laryngeal Neoplasms 1Glioma 1Ganglioneuroblastoma 1Craniopharyngioma 1Carcinoma 1Astrocytoma 1

Interventions

Specimen Handling 12Magnetic Resonance Spectroscopy 12Temozolomide 11Radiotherapy 8Radiation 5Surgical Procedures, Operative 3Biopsy 3trametinib 2dabrafenib 2Spinal Puncture 2Radiotherapy, Intensity-Modulated 2Genetic Therapy 2Craniotomy 2Bevacizumab 2vorasidenib 1vocimagene amiretrorepvec 1veliparib 1trastuzumab deruxtecan 1tocilizumab 1ribociclib 1pembrolizumab 1atezolizumab 1abexinostat 1Vorinostat 1Transurethral Resection of Bladder 1Standard of Care 1Restraint, Physical 1Protons 1Proton Therapy 1Practice Guidelines as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Astrocytoma × Transurethral Resection of Bladder × 90 days × Clear all
NCT07468136 2026-04-13

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Mayo Clinic

Phase 1/2 Not yet recruiting
33 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡